At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
PEG IFN alfa-2a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta
In Brief
A Phase 2 clinical trial evaluating PEG IFN alfa-2a and Myrcludex B for Chronic Hepatitis D Infection. Completed, enrolled 24 participants.
Detailed Summary
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis D Infection
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedDec 2015
Primary CompletionJan 2016
TodayJul 2026
First PostedDec 22, 2015
Enrollment StartFeb 13, 2014
Primary CompletionJan 21, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.5 years ago
Interventions
PEG IFN alfa-2adrug
Myrcludex Bdrug